During the presentation, I’ll describe how innovation rarely follows a linear path, and how technology delays and regulatory change require decisions to be revisited after capital has already been deployed — with a focus on maintaining strategic intent and building value for investors.

With resistance to existing parasiticides rising and few new molecules in decades, ASTRA Therapeutics set out to change the game. Co-CEOs Natacha Gaillard and Ashwani Sharma share how the company closed one of the largest seed rounds in animal health, positioned itself to deliver precision-designed antiparasitics, and built investor confidence in solving one of animal health’s most urgent challenges.

Let’s dive into:

- Rising opportunities driven by the growing market for veterinary

biological drugs and social trends

- First-of-a-kind donor-based cell therapy that’s shaping the future of pet medicine

- Successful clinical trials results for osteoarthritis in dogs, atopic dermatitis in dogs, osteoarthritis in horses